Table 2 Association of Polymorphisms cMyc-N11S and p27-V109G with Breast Cancer Risk
From: Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis
| Â | Total | White | ||||||
|---|---|---|---|---|---|---|---|---|
| Â | Cases (N = 1,115) | Controls (N = 710) | Unadjusted OR (95% CI) | Age and race-adjusted OR (95% CI) | Cases (N = 1,079) | Controls (N = 677) | Unadjusted OR (95% CI) | Age-adjusted OR (95% CI) |
cMyc-N11S (A>G) | Â | Â | Â | Â | Â | Â | Â | Â |
AA | 1011 (91.9%) | 653 (91.8%) | 1.00 | 1.00 | 976 (91.7%) | 621 (91.7%) | 1.00 | 1.00 |
AG/GG | 89 (8.1%) | 57 (8.0%) | 1.00 (0.71–1.43) | 1.15 (0.73–1.82) | 88 (8.4%) | 56 (8.3%) | 1.00 (0.71–1.42) | 1.18 (0.75–1.87) |
p27-V109G (T>G) | Â | Â | Â | Â | Â | Â | Â | Â |
TT | 668 (61.5%) | 405 (59.8%) | 1.00 | 1.00 | 644 (61.1%) | 393 (59.7%) | 1.00 | 1.00 |
TG | 366 (33.7%) | 243 (35.9%) | 0.91 (0.75–1.12) | 0.70 (0.52–0.93) | 359 (34.1%) | 238 (36.2%) | 0.92 (0.75–1.13) | 0.71 (0.53–0.94) |
GG | 53 (4.9%) | 29 (4.3%) | 1.11 (0.69–1.77) | 0.83 (0.42–1.65) | 51 (4.8%) | 27 (4.1%) | 1.15 (0.71–1.87) | 0.84 (0.42–1.67) |
Combined | Â | Â | Â | Â | Â | Â | Â | Â |
cMyc AA + p27 TT | 611 (56.4%) | 369 (54.5%) | 1.00 | 1.00 | 588 (56.0%) | 357 (54.3%) | 1.00 | 1.00 |
cMyc AA + p27 TG/GG | 386 (35.6%) | 253 (37.4%) | 0.92 (0.75–1.13) | 0.92 (0.74–1.13) | 377 (35.9%) | 246 (37.4%) | 0.93 (0.76–1.15) | 0.70 (0.52–0.94) |
cMyc AG/GG + p27 TT | 55 (5.1%) | 36 (5.3%) | 0.92 (0.59–1.43) | 0.96 (0.61–1.51) | 54 (5.1%) | 36 (5.5%) | 0.91 (0.59–1.42) | 0.98 (0.55–1.74) |
cMyc AG/GG + p27 TG/GG | 32 (3.0%) | 19 (2.8%) | 1.02 (0.57–1.82) | 1.08 (0.59–1.98) | 32 (3.0%) | 19 (2.9%) | 1.02 (0.57–1.83) | 0.99 (0.45–2.19) |